Free Standard AU & NZ Shipping For All Book Orders Over $80!
Register      Login
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
Shopping Cart: ( empty )
You are here: Home > Journals > SH > SH10088
EDITORIAL
Contents Vol 7(3)

Advancements in the control of genital human papillomavirus infections and related diseases: highlighting Australia’s role

Suzanne M. Garland A B C D H , Julia M. L. Brotherton E , Christopher K. Fairley F G , Dorota M. Gertig E and Marion Saville E
+ Author Affiliations
- Author Affiliations

A Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Locked Bag 300, Parkville, Vic. 3052, Australia.

B Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Vic. 3052, Australia.

C Murdoch Childrens Research Institute, University of Melbourne, Parkville, Vic. 3052, Australia.

D Department of Microbiology, Royal Children’s Hospital, Parkville, Vic. 3052, Australia.

E Victorian Cytology Service, PO Box 161, Carlton South, Vic. 3053, Australia.

F School of Population Health, University of Melbourne, Carlton, Vic. 3053, Australia.

G Melbourne Sexual Health Centre, 580 Swanston Street, Carlton, Vic. 3053, Australia.

H Corresponding author. Email: Suzanne.garland@thewomens.org.au

Sexual Health 7(3) 227-229 https://doi.org/10.1071/SH10088
Submitted: 20 July 2010  Accepted: 26 July 2010   Published: 19 August 2010


References


[1] Rigoni-Stern D. Fatti statistici relativi alle malattic cancerose. Giorn Prog Patol Terap 1842; 2 507–17.


[2] Gagnon F. Contribution to the study of the etiology and prevention of cancer of the cervix of the uterus. Am J Obstet Gynecol 1950; 60 516–22.
|  CAS | PubMed |

[3] Gissmann LWL,  Ikenberg H,  Koldovsky U,  Schnurch HG,  zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci USA 1983; 80 560–3.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |

[4] Zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 1977; 78 1–30.
|  CAS | PubMed |

[5] Bosch F,  Lorincz A,  Munoz N,  Meijer C. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55 244–65.
|  CAS | PubMed |

[6] Munoz N,  Bosch FX,  de Sanjose S,  Herrero R,  Castellsague X,  Shah KV, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348 518–27.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[7] Stevens MP,  Tabrizi SN,  Quinn MA,  Garland S. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial or cervical cancer in Melbourne, Australia. Int J Gynecol Cancer 2006; 16 1017–24.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |

[8] Laverty CR,  Russell P,  Hills E,  Booth N. The significance of non-condylomatous wart virus infection of the cervical transformation zone: a review with discussion of two illustrative ubular strictures cases. Acta Cytol 1978; 22 195–201.
|  CAS | PubMed |

[9] Hills E,  Laverty CR. Electron microscopic detection of papilloma virus particles in selected koilocytotic cells in a routine cervical smear. Acta Cytol 1979; 23 53–6.
|  CAS | PubMed |

[10] Kirnbauer R,  Booy F,  Cheng N,  Lowy DR,  Schiller J. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89 12180–4.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |

[11] Frazer IH. Cervical cancer vaccine development. Sex Health 2010; 7 230–4.
| Crossref | GoogleScholarGoogle Scholar |

[12] Zhou J,  Sun XY,  Stenzel DJ,  Frazer IH. Expression of vaccinia recombinant HP V 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185 251–7.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |

[13] Rose RC,  Bonnez W,  Reichman RC,  Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of virus-like particles. J Virol 1993; 67 1936–44.
|  CAS | PubMed |

[14] Paavonen J,  Naud P,  Salmeron J,  Wheeler CM,  Chow SN,  Apter DL, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374 301–14.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |

[15] FUTURE II SG Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356 1915–27.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[16] Garland SM,  Hernandez AM,  Wheeler CM,  Perez G,  Harper DM,  Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356 1928–43.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |

[17] Paavonen J,  Jenkins D,  Bosch FX,  Naud P,  Salmerón J,  Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369 2161–70.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |

[18] Gertig DM,  Brotherton JML,  Saville M. Methods for measuring human papillomavirus vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2010;
| Crossref | GoogleScholarGoogle Scholar |

[19] Joseph T,  Menzies R. Human papillomavirus vaccination and Australian Indigenous women. Sex Health 2010;
| Crossref | GoogleScholarGoogle Scholar |

[20] Brotherton JML,  Kaldor JM,  Garland SM. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy. Sex Health 2010; 7 310–19.
| Crossref | GoogleScholarGoogle Scholar |

[21] Cooper Robbins SC,  Bernard D,  McCaffery K,  Skinner SR. ‘It’s a logistical nightmare!’: Recommendations for optimising human papillomavirus school-based vaccination experiences. Sex Health 2010; 7 271–8.
| Crossref | GoogleScholarGoogle Scholar |

[22] Fairley C,  Hocking J,  Chen M,  Donovan B,  Bradshaw C. Rapid decline in warts after national quadrivalent HPV vaccine program. Sex Transm Infect 2009; 85 499–502.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |

[23] Fairley CK,  Donovan B. What can surveillance of genital warts tell us? Sex Health 2010; 7 325–7.
| Crossref | GoogleScholarGoogle Scholar |

[24] Grulich AE,  Jin F,  Conway EL,  Stein AN,  Hocking J. Cancers attributable to human papillomavirus infection. Sex Health 2010; 7 244–52.
| Crossref | GoogleScholarGoogle Scholar |

[25] Novakovic D,  Cheng ATL,  Cope DH,  Brotherton JML. Estimating the prevalence of and treatment patterns for juvenile onset recurrent respiratory papillomatosis in Australia pre-vaccination: a pilot study. Sex Health 2010; 7 253–61.
| Crossref | GoogleScholarGoogle Scholar |

[26] Garland SM,  Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs 2010; 70 1079–98.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[27] Nghi NQ,  LaMontagne SD,  Bingham A,  Rafiq M,  Mai LTP,  Lien NTP, et al. Human papillomavirus vaccine introduction in Vietnam: formative research findings. Sex Health 2010; 7 262–70.
| Crossref | GoogleScholarGoogle Scholar |

[28] Canfell K. Models of cervical screening in the era of human papillomavirus vaccination. Sex Health 2010; 7 359–67.
| Crossref | GoogleScholarGoogle Scholar |

[29] Zerhouni EA. Translational and clinical science – time for a new vision. N Engl J Med 2005; 353 1621–3.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |